Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors-Reference-Cited by-同舟云学术

Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors

Published:2019-10-27 Issue:3 Volume:18 Page:72-80
ISSN:1819-3684
Container-title:Bulletin of Siberian Medicine
language:
Short-container-title:Bûll. sib. med.

Author:

Larkina M. S.¹,Podrezova E. V.²,Bragina O. D.³,Tagirova E. A.²,Chernov V. I.³,Yusubov M. S.²,Nesterov E. A.²,Skuridin V. S.²,Krivoshchekov S. V.⁴,Yanovskaya E. A.⁵,Gurto R. V.⁵,Belousov M. V.¹

Affiliation:

1. Siberian State Medical University (SSMU)

2. National Research Tomsk Polytechnic University (NR TPU)

3. Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Science

4. Siberian State Medical University (SSMU); National Research Tomsk Polytechnic University (NR TPU)

5. Goldberg Research Institute of Pharmacology and Regenerative Medicine (GRIPhRM), Tomsk National Research Medical Center (NRMC), Russian Academy of Science

Abstract

Currently the development of technologies for labeling somatostatin with technetium-99m for diagnosing radionuclide neuroendocrine tumors is under way. Somatostatin analogues are binded with technetium99m only by the preliminary addition of a chelating agent. Therefore, it is important to develop a method for preparation of an octreotide derivative by modifying octreotide with precursors: ligands with high chelating ability for its tight binding with technetium-99m. ω-Bis(pyridin-2-ylmethyl)amino)aliphatic acids can be used successfully as such precursors.The purpose of the study was to develop a method for obtaining a new octreotide derivative for diagnosing neuroendocrine tumors.Materials and methods. The somatostatin octreotide analogue was used as the object of the study; succinimid-1-yl 6-(bis(pyridin-2-ylmethyl)amino)hexanoate was used as a chelating agent. Methods of high performance liquid chromatography and mass spectrometry were used to separate and analyze the synthesized compounds.Results. A method to produce an original octreotide derivative using a succinimid-1-yl 6-(bis(pyridin2-ylmethyl)amino)hexanoate as a chelating agent was proposed. The conditions of analytical and semipreparative HPLC for the analysis and purification of the active octreotide derivative (a monosubstituted derivative of the amino acid residue of D-phenylalanine) were suggested.Conclusion. The synthesized derivative of octreotide has a chelating center for strong binding to technetium-99m in its structure, which can be useful for diagnosing neuroendocrine tumors.

Publisher

Siberian State Medical University

Subject

Molecular Medicine

Reference20 articles.

1. Sundin A., Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology. 2012; 96 (4): 261–271. DOI: 10.1159/000342270.

2. Oberg K.E., Reubi J.C., Kwekkeboom D.J. et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139 (3): 742–753. DOI: 10.1053/j.gastro.2010.07.002.

3. Eads J.R., Meropol N.J. A New Era for the Systemic Therapy of Neuroendocrine Tumors. The Oncologist. 2012; 17 (3): 326–338. DOI: 10.1634/theoncologist.2011-0356.

4. Strosberg J.R., Fine R.L., Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117: 268–275. DOI: 10.1002/cncr.25425.

5. Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy: current state of the problem. Vestnik Rentgenologii and Radiologii. 2016; 62 (1): 24–30 (in Russ.).